Industry News

Delta Corp. Ltd, the company focused on casinos in Goa, has entered the real estate investment business through his new Rs.500 crore private equity fund. Ltd has launched the fund, Alpha Advantage Real Estate Fund, with a green shoe option of an additional Rs.500 crore, a senior executive said. A green shoe option allows the fund to raise more money than originally planned."/>
Delta Corp. founder Jaydev Mukund Mody launches Rs500 crore realty fund [Mint, New Delhi]
Altru welcomes 3D mammography equipment [Grand Forks Herald]
GW Pharmaceuticals plc,,, a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced today the pricing of an underwritten public offering by the Company. GW will issue 2,800,000 of American Depositary Shares, representing 33,600,000 ordinary shares of GW, at a price to the public of $90.00 per ADS on the NASDAQ Global Market, raising gross proceeds..."/>
GW Pharmaceuticals plc Announces Pricing of U.S. Public Offering of ADSs Raising $252.0 Million on NASDAQ Global Market
BARNES GROUP TO ACQUIRE ADVAL TECH'S MOULDS BUSINESS FOR CHF 133 M US-based aerospace and industrial manufacturing and service provider Barnes Group Inc. has entered into a definitive agreement to acquire Swiss mold-making specialist Adval Tech's molds business, the company said. FOBOHA focused on the development and manufacture of complex plastic injection molds for packaging, medical,..."/>
M and A Navigator: Deal pipeline –13 July
RespireRx Pharmaceuticals Inc., a leader in the development of medicines for respiratory disorders, including sleep apneas and drug-induced respiratory depression, announced that the Company's President, CEO and Vice Chairman of the Board of Directors, James S. Manuso, Ph.D., will present at the Cantor Fitzgerald 2nd Annual Healthcare Conference in New York, New York on Wednesday, July 13, 2016, at 9:30 a.m. Eastern Time. The Conference is being sponsored..."/>
RespireRx Pharmaceuticals Inc. to Present at the Cantor Fitzgerald 2nd Annual Healthcare Conference on July 13, 2016
Shire plc announces that the U.S. Food and Drug Administration has approved Xiidra 5%, a twice-daily eye drop solution indicated for the treatment of the signs and symptoms of dry eye disease in adult patients. Xiidra is the only prescription eye drop indicated for the treatment of both signs and symptoms of this condition."/>
Multimedia assets now available: FDA Approves Shire's Xiidra™ (lifitegrast ophthalmic solution) 5% - The Only Treatment Indicated for the Signs and Symptoms of Dry Eye Disease
Mednax, Inc. has acquired Fairfax, Virginia-based private physician group Pediatric Cardiology Associates, the company said. Terms of the deal were not disclosed. This was a cash transaction, and it is expected to be immediately accretive to earnings."/>
US Physician Services Provider Mednax Acquires Cardiology Practice in Virginia
Sagent Pharmaceuticals, Inc. have agreed to a merger in which Nichi-Iko will acquire Sagent for a total consideration of approximately USD736m, the company said. The acquisition is subject to the satisfaction of customary conditions, including the valid tender of a majority of the outstanding Sagent shares on a fully-diluted basis."/>
Japan’s Nichi-Iko Pharmaceutical to Acquire Hospital Supplier Sagent for USD 736m
Juno Therapeutics Inc. concerning possible violations of federal securities laws. If you purchased shares of Juno and want more information, please contact Joon M. Khang, Esquire, of Khang& Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: 419-3834, or by e-mail at There has been no class certification in this case."/>
INVESTOR NOTICE: Khang & Khang LLP Announces an Investigation of Juno Therapeutics Inc. and Reminds Investors With Losses to Contact the Firm
Pacific Biosciences of California, Inc. will hold its quarterly conference call to discuss its Second Quarter 2016 Financial Results on Thursday, August 4, 2016, at 4:30pm Eastern Time.. The call will be webcast and may be accessed at Pacific Biosciences’ website at: About Pacific Biosciences Pacific Biosciences of California, Inc. offers sequencing systems to help scientists resolve genetically..."/>
Pacific Biosciences of California, Inc. Second Quarter 2016 Financial Results Call
CryoLife, Inc., a leading medical device and tissue processing company focused on cardiac surgery, announced today that 2016 second quarter financial results will be released on Monday, July 25, 2016 after the market closes. On Tuesday, July 26, 2016 the Company will hold a teleconference call and live webcast at 8:00 a.m. ET to discuss the results, followed by a question and answer session hosted by J. Patrick Mackin, Chairman, President and Chief..."/>
CryoLife Announces Release Date and Teleconference Call Details for 2016 Second Quarter Financial Results
Invuity, Inc., a leading surgical photonics company, today announced that it will release its 2016 second quarter and six-month financial results after the market closes on Tuesday, July 19, 2016. In conjunction with the release, the Company will host a conference call with the investment community at 2:00 p.m. Pacific Time/ 5:00 p.m. Eastern Time on Tuesday, July 19, 2016, to discuss the financial results and other business developments.."/>
Invuity Announces 2016 Second Quarter, Six-Month Results Release and Conference Call Date
Sagent Pharmaceuticals, Inc. for potential breaches of fiduciary duties in connection with the sale of the Company to Nichi-Iko Pharmaceutical Co., Ltd. for approximately $736 million. The Company's stockholders will only receive $21.75 in cash for each share of Company common..."/>
SAGENT SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces the Investigation of Sagent Pharmaceuticals, Inc. (SGNT) Over the Proposed Sale of the Company to Nichi-Iko Pharmaceutical Co., Ltd.
Sagent Pharmaceuticals, Inc. in connection with the proposed acquisition of the Company by Nichi-Iko Pharmaceutical Co.. On July 11, 2016, the Company announced that it had reached a definitive agreement for Nichi-Iko to acquire all outstanding shares of SGNT in a transaction valued at $736 million."/>
Sagent Pharmaceuticals, Inc. Acquisition May Not Be in the Best Interests of SGNT Shareholders
Juno Therapeutics, Inc., a biopharmaceutical company focused on re-engaging the body’ s immune system to revolutionize the treatment of cancer, today announced that the U.S. Food and Drug Administration has removed the clinical hold on the Phase II clinical trial of JCAR015 in adult patients with relapsed or refractory B cell acute lymphoblastic leukemia. Under the revised protocol, the ROCKET trial will continue enrollment using JCAR015 with cyclophosphamide..."/>
Juno Therapeutics to Resume JCAR015 Phase II ROCKET Trial
Vanda Pharmaceuticals Inc. today announced it will release results for the second quarter of 2016 on Wednesday, July 27, 2016, after the market closes. Vanda will host a conference call at 4:30 PM ET on Wednesday, July 27, 2016, during which management will discuss the second quarter 2016 financial results and other corporate activities. To participate in the conference call, please dial 1-888-771-4371 or 1-847-585-4405 and use passcode..."/>
Vanda Pharmaceuticals to Announce Second Quarter 2016 Financial Results on July 27, 2016
Canopy Growth Corporation recently granted an aggregate of 250,000 options to purchase common stock to two Officers of the Corporation to be vested in accordance to the terms of the Corporation's Option Plan. All of the foregoing options shall have an exercise price equal to $2.68 per share. About Canopy Growth Corporation Canopy Growth is a world-leading diversified cannabis company, offering diverse brands and curated cannabis strain..."/>
Canopy Growth Corporation Issues Options
Tonix Pharmaceuticals Holding Corp., today announced that the underwriters of Tonix’ s previously announced public offering that initially closed on June 21, 2016, have purchased an additional 750,000 shares of Tonix’ s common stock at a price of $2.00 per share, before deducting the underwriting discount, in connection with the exercise in full of their over-allotment option. Tonix has now sold a total of 5,750,000 shares of its common stock in..."/>
Tonix Pharmaceuticals Announces Full Exercise and Closing of Underwriters’ Over-Allotment Option
Exelixis, Inc. announced today that its second quarter 2016 financial results will be released on Wednesday, August 3, 2016 after the markets close. At 5:00 p.m. EDT/ 2:00 p.m. PDT, Exelixis management will host a conference call to discuss the results and provide a general business update."/>
Exelixis to Release Second Quarter 2016 Financial Results on Wednesday, August 3, 2016
Inotek Pharmaceuticals Corporation, a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for glaucoma and other eye diseases, today announced the initiation of a Phase 2 dose-ranging trial of a fixed-dose combination of trabodenoson and latanoprost. Glaucoma is one of the leading causes of blindness, and occurs when there is damage to the optic nerve as a result of elevated eye pressure."/>
Inotek Pharmaceuticals Initiates Phase 2 Dose-ranging Trial of a Fixed-Dose Combination of Trabodenoson, a Novel Treatment for Glaucoma, and Latanoprost

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Financials970 Articles
Information Technology928 Articles
Consumer Discretionary786 Articles
Industrials615 Articles
Health Care603 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at